Gsk (GSK) Cash & Current Investments (2009 - 2026)

Gsk's Cash & Current Investments history runs 18 years deep, the most recent figure standing at $4.0 billion for Q2 2026.

• In Q2 2026, Cash & Current Investments fell 21.96% year-over-year to $4.0 billion; the TTM figure through Jun 2026 stood at $4.0 billion (down 21.96% YoY), while the FY2025 annual figure was $4.6 billion, down 8.8% from the prior year.
• Cash & Current Investments for Q2 2026 stood at $4.0 billion, down from $4.4 billion in the prior quarter.
• The five-year high for Cash & Current Investments was $8.3 billion in Q2 2022, with the low at $484.4 million in Q1 2022.
• The 5-year median for Cash & Current Investments is $4.3 billion (2023), against an average of $4.3 billion.
• The sharpest annual moves came in 2022 and 2023: Cash & Current Investments sank 92.96% in 2022, then surged 656.55% in 2023.
• Gsk's Cash & Current Investments stood at $4.4 billion in 2022, then fell by 14.4% to $3.8 billion in 2023, then soared by 34.21% to $5.1 billion in 2024, then slipped by 8.37% to $4.7 billion in 2025, then declined by 15.48% to $4.0 billion in 2026.
• Business Quant data shows GSK's Cash & Current Investments at $4.0 billion in Q2 2026, $4.4 billion in Q1 2026, and $4.7 billion in Q4 2025.